Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Conditions: Recurrent Acute Leukemia; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hairy Cell Leukemia; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent T Acute Lymphoblastic Leukemia; Refractory Acute Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Hairy Cell Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory T Acute Lymphoblastic Leukemia; Systemic Mastocytosis
Interventions: Drug: Acetaminophen; Drug: Dexamethasone; Drug: Diphenhydramine; Biological: Flotetuzumab; Drug: Ibuprofen; Drug: Ranitidine
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
December 24, 2020 /
/ in Oncology